Emergency Preparedness and Response

About MCMi

The Medical Countermeasures Initiative (MCMi) is an FDA-wide initiative to coordinate medical countermeasure development, preparedness and response, led by the Office of Counterterrorism and Emerging Threats in the Office of the Chief Scientist.

FDA plays a critical role in protecting the United States from chemical, biological, radiological, nuclear, and emerging infectious disease threats. FDA ensures that medical countermeasures (MCMs)—including drugs, vaccines and diagnostic tests—to counter these threats are safe, effective, and secure.

MCMi logo – four diamond shapes with radiological and biohazard symbols, globe and test tube

Together with U.S. government partners through the Department of Health and Human Services Public Health Emergency Medical Countermeasures Enterprise, FDA helps define and prioritize requirements for MCMs in public health emergencies. This includes coordinating research, setting deployment and use strategies, and facilitating access to MCMs.

Learn more about MCMi's history. 

Information in this Section

Related Information

FDA's strategic priorities include medical countermeasures and emergency preparedness


Sign up to receive email alerts on emergency preparedness and response topics from FDA, including medical countermeasures and emerging infectious diseases.

Page Last Updated: 04/14/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English